You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Dow
Merck
Boehringer Ingelheim

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022334


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

NDA 022334 describes AFINITOR, which is a drug marketed by Novartis and Novartis Pharm and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug and three Paragraph IV challenges. Additional details are available on the AFINITOR profile page.

The generic ingredient in AFINITOR is everolimus. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the everolimus profile page.
Summary for 022334
Tradename:AFINITOR
Applicant:Novartis
Ingredient:everolimus
Patents:7
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022334
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AFINITOR everolimus TABLET;ORAL 022334 NDA Novartis Pharmaceuticals Corporation 0078-0566 0078-0566-51 28 BLISTER PACK in 1 CARTON (0078-0566-51) > 1 TABLET in 1 BLISTER PACK (0078-0566-61)
AFINITOR everolimus TABLET;ORAL 022334 NDA Novartis Pharmaceuticals Corporation 0078-0567 0078-0567-51 28 BLISTER PACK in 1 CARTON (0078-0567-51) > 1 TABLET in 1 BLISTER PACK (0078-0567-61)
Paragraph IV (Patent) Challenges for 022334
Tradename Dosage Ingredient NDA Submissiondate
AFINITOR TABLET;ORAL everolimus 022334 2014-12-10
AFINITOR TABLET;ORAL everolimus 022334 2014-06-18

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Mar 30, 2009TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Oct 26, 2019
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Regulatory Exclusivity Expiration:Feb 26, 2019
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
Regulatory Exclusivity Expiration:Feb 26, 2023
Regulatory Exclusivity Use:TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

Expired US Patents for NDA 022334

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009   Start Trial   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010   Start Trial   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
AstraZeneca
McKinsey
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.